Drugs that contain Vilazodone Hydrochloride

1. List of Viibryd drug patents

VIIBRYD Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7834020 ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(9 months ago)

US8673921 ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(9 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8236804 ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Jun, 2022

(9 months ago)

US8193195 ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(9 months ago)

US7834020

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(3 months ago)

US8193195

(Pediatric)

ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(3 months ago)

US8236804

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Dec, 2022

(3 months ago)

US8673921

(Pediatric)

ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(3 months ago)

Exclusivity Exclusivity Expiration
M (M) Jan 31, 2023
Pediatric Exclusivity (PED) Jul 31, 2023

Market Authorisation Date: 21 January, 2011

Treatment: Treatment of major depressive disorder (mdd)

Dosage: TABLET;ORAL

How can I launch a generic of VIIBRYD before it's patent expiration?
More Information on Dosage

VIIBRYD family patents

16

Canada

15

United States

3

Japan

3

European Union

2

Slovakia

2

Hong Kong

2

Czech Republic

2

China

1

Israel

1

South Africa

1

Denmark

1

Austria

1

Mexico

1

Australia

1

Russia

1

Hungary

1

Germany

1

Argentina

1

Brazil

1

Portugal

1

Cyprus

1

Malaysia

1

Spain

1

Korea, Republic of

1

Poland

1

Ecuador

1

Ukraine

1

Estonia

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic